{"schema_version":"secwatch.filing_event.v1","accession":"0000914121-23-000149","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.193832+00:00","generated_at":"2026-06-17T08:58:29.782340+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics Q3 net sales up 9% but guides down; adjusted EPS loss $0.03 vs prior guidance for profit","bullets":["Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.","Med Tech sales $22.9M (+16.6%); Auryon +42.8% to $10.4M; AngioVac -15.7% to $5.5M.","Gross margin 50.2%, down 200 bps YoY; adjusted EBITDA $4.3M vs $6.7M.","FY2023 guidance cut: net sales now $338-342M (from $342-348M); adjusted EPS now loss $0.06 to loss $0.01 (from profit $0.01-0.06).","Cash $30.1M; total debt $50M; generated $1.4M operating cash in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000914121-23-000149","json":"https://secwatch.observer/filing/0000914121-23-000149.json","markdown":"https://secwatch.observer/filing/0000914121-23-000149.md","text":"https://secwatch.observer/filing/0000914121-23-000149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/0000914121-23-000149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/an59017198-8ki.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:58:29.782340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42a1153b8824cb6fd36499508c15456d22350530","claim":"ANGIODYNAMICS INC reported the third quarter of fiscal year 2023, which ended February 28, 2023 results: revenue $80.7 million, net income net loss of $9.5 million, or a loss per share of $0.24, EPS loss per share of $0.24. Guidance lowered.","evidence_excerpt":"Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 Third Quarter Highlights • Net sales of $80.7 million increased 9.1% compared to the prior-year quarter o Med Tech net sales of $22.9 million increased 16.6% o Med Device net sales of $57.8 million increased 6.4% • Gross margin of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1275187/000091412123000149/0000914121-23-000149-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of fiscal year 2023, which ended February 28, 2023"},{"label":"Revenue","value":"$80.7 million"},{"label":"Net income","value":"net loss of $9.5 million, or a loss per share of $0.24"},{"label":"EPS","value":"loss per share of $0.24"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}